Cositecan is the novel camptothecin derivative which is also known as Karenitecin. It has been developed for superior oral bioavailability and increased lactone stability. It is used to treat cancer.
- Mechanism
- Curator reviewed
BNP1350, 7-[(2-trimethylsilyl)ethyl]-20(S)-camptothecin, is a novel semi-synthetic, highly lipophilic, silicon-containing camptothecin and an inhibitor of topoisomerase I. It has been supercomputer engineered for superior oral bioavailability, superior lactone stability, broad anti-tumor activity, increased potency and insensitivity to Pgp/MRP/LRP drug resistance.
- Primary indication
- Investigated for use/treatment in brain cancer, lung cancer, and melanoma.Curator reviewed
- Formula / weight
- C25H28N2O4Si · 448.5863 g/mol (avg)
- Also known as
- Karenitecin
- Code names
- BNP 1350 · DB 172
Resolves to
POADTFBBIXOWFJ-VWLOTQADSA-NSMILESCC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C(CC[Si](C)(C)C)C4=CC=CC=C4N=C13)C2=OWhat you can answer from here — as of June 15, 2026
Which drugs share a target with Cositecan, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account